Brochure: Crystal16 the next generation
Improve and accelerate your crystallisation screening with the Crystal16 parallel crystalliser.
List view / Grid view
Improve and accelerate your crystallisation screening with the Crystal16 parallel crystalliser.
Request your Proficiency Testing (PT) samples to ensure your elemental impurity analysis is compliant with ICH Q3D guideline or any other ICP analysis.
Microcaps exceeds stringent requirements beyond taste masking.
Ten major tips for optimising techniques used by pharmaceutical research labs in their work on discovery and development of novel compounds.
Save time with the feedback control option at the Crystal16 and the CrystalBreeder. Simplify crystallisation by automating your process.
Case study example regarding finding impurities and controlling formations at release.
In this in-depth focus, experts discuss why nanoparticles are a promising alternative for delivering inflammatory bowel disease therapies and highlight the potential of antibody-drug conjugates to advance oncology treatment.
European Pharmaceutical Review's latest journal features articles discussing the challenges and potential of antibody-drug conjugates, innovations in cleanroom infrastructure and why we need to test for heavy metal contaminants in cannabis vaping aerosols. Also in the issue, an exploration of how risk-sharing strategies could help expedite access to COVID-19 vaccines,…
Challenges and solutions to adopting MALDI technology for filamentous fungi ID with emphasis on sample preparation and database development.
Overview of Adare Pharma Solutions- a leading global CDMO with innovative oral dose technology platforms.
Manufacturing drug products with low solubility APIs (BCS type II and IV) has its challenges, in this article, Javier Gurrea, a Spray Drying Manufacturing Scientist at Idifarma, explains why spray drying offers a great way to overcome them.
Continuous wet granulation and drying have long been a hot topic in pharmaceutical manufacturing. The QbCon® 1 system solves all existing problems.
The journey from large molecule to approved biotherapeutic is long, costly, complex, and fraught with risk – yet rewards for success are substantial.
The European Medicines Agency has published its recommendations for 2021-2022 seasonal influenza vaccine composition.
A framework to enable a holistic approach to CCI that assures both primary packaging and process contribute to good CCI of sterile vial product.